View source for Mirabegron

{{MedTemplate
| generic           = Mirabegron
| brand             = Myrbetriq
| structure         =
| classes           = [[:Category:Beta-3_agonists|β3 adrenergic agonist]], [[:Category:Overactive_bladder_medications|Overactive bladder medication]]
| uses              = <vote slug="overactive-bladder-use">Overactive bladder (urgency, frequency, urge incontinence)</vote>, <vote slug="neurogenic-bladder-use">Neurogenic detrusor overactivity</vote>
| starting_dose     = 25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed
| preparations      = 25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric)
| fda_max           = 50 mg/d
| pill_id           =
| routes            = Oral
| onset             = Symptom improvement within weeks
| duration          = 24 hours
| halflife          = ~50 hours<ref name="myrbetriq-label">FDA Prescribing Information, Myrbetriq (mirabegron), Astellas, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202611s015lbl.pdf</ref>
| bioavailability   = 25 mg: ~29%; 50 mg: ~35%; food reduces absorption<ref name="myrbetriq-label" />
| pregnancy         = Limited data.{{citation needed}}
| legal             = [[USLegal:Prescription only|Rx-only]] in US
| mechanism         = <vote slug="mirabegron-mech-claim">Mirabegron selectively activates β3 adrenergic receptors on detrusor smooth muscle, relaxing the bladder during filling and increasing functional bladder capacity without the anticholinergic burden of muscarinic-antagonist therapy.</vote> The mechanistically distinct profile makes it the preferred OAB agent in older adults at risk from cumulative anticholinergic exposure. Modest BP elevation (especially in untreated hypertension) and atrial fibrillation signals limit use in some patients. CYP2D6 substrate AND moderate inhibitor — clinically relevant interaction with metoprolol and other CYP2D6 substrates<ref name="myrbetriq-label" />.
}}

== References ==
<references />